FrancophonIA/ELRC3.0 huggingface dataset:
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg/20 mL
Croatian: SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 100 mg/20 ml
English: A formal interaction study showed that the pharmacokinetic characteristics of cetuximab remain unaltered after co-administration of a single dose of irinotecan (350 mg/m2 body surface area).
Croatian: Formalno kliničko ispitivanje interakcije pokazalo je da farmakokinetičke karakteristike cetuksimaba ostaju nepromijenjene nakon istodobne primjene pojedinačne doze irinotekana (350 mg/m2 tjelesne površine).
English: Infusion-related, including anaphylactic, reactions
Croatian: Reakcije povezane s infuzijom uključujući anafilaktičku reakciju
English: In the overall population, irrespective of KRAS status, the results reported for cetuximab plus irinotecan (648 patients) vs. irinotecan alone (650 patients) were: median overall survival time (OS) 10.71 vs. 9.99 months (HR 0.98), median progression free survival time (PFS) 4.0 vs. 2.6 months (HR 0.69), and objective response rate (ORR) 16.4% vs. 4.2%.
Croatian: U ukupnoj populaciji, neovisno o statusu KRAS-a, prijavljeni rezultati za cetuksimab i irinotekan (648 bolesnika) naspram samog irinotekana (650 bolesnika) iznosili su: medijan ukupnog vremena preživljenja (OS) 10,71 naspram 9,99 mjeseci (HR 0,98), medijan vremena preživljenja bez napredovanja bolesti (PFS) 4,0 naspram 2,6 mjeseci (HR 0,69) i stopa objektivnog odgovora (ORR) 16,4% naspram 4,2%.
English: Symptoms may occur during the first infusion and for up to several hours afterwards or with subsequent infusions.
Croatian: Simptomi se mogu javiti tijekom početne infuzije, ali i nakon nekoliko sati ili pri sljedećim infuzijama.
English: If keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered.
Croatian: U slučaju dijagnosticiranog keratitisa potrebno je pažljivo razmotriti dobrobiti i rizike nastavka liječenja.
English: The main side effects of Erbitux are infusion-related side effects and side effects concerning the skin: Infusion-related side effects
Croatian: Glavne nuspojave Erbituxa su nuspojave povezane s infuzijom i nuspojave povezane s kožom: Nuspojave povezane s infuzijom
English: Mean peak cetuximab concentrations were 155.8 microgram per mL in week 3 and 151.6 microgram per mL in week 8, whereas the corresponding mean trough concentrations were 41.3 and 55.4 microgram per mL, respectively.
Croatian: Srednje vršne koncentracije cetuksimaba iznosile su 155,8 mikrograma po ml u tjednu 3 i 151,6 mikrograma po ml u tjednu 8 gdje je odgovarajuća prosječna najniža koncentracija iznosila 41,3 mikrograma, odnosno 55,4 mikrograma po ml.
English: Approximately 75% of the patients with metastatic colorectal cancer screened for clinical studies had an EGFR-expressing tumour and were therefore considered eligible for cetuximab treatment.
Croatian: Otprilike 75% bolesnika s metastatskim kolorektalnim karcinomom koji su probrani za klinički pokus imalo je tumor koji iskazuje EGFR i time su smatrani pogodnima za liječenje cetuksimabom.
English: • decrease in blood levels of magnesium
Croatian: • smanjenje razine magnezija u krvi
English: Erbitux is usually infused once a week.
Croatian: Erbitux se obično primjenjuje infuzijom jednom tjedno.
English: The RAS mutant population comprises these 65 patients together with 113 patients with KRAS exon 2 mutant tumours treated before study enrolment was restricted to patients with KRAS exon 2 wild-type mCRC.
Croatian: Populacija s mutacijama RAS-a obuhvaćala je tih 65 bolesnika zajedno sa 113 bolesnika s tumorima s mutacijom eksona 2 KRAS-a liječenih prije nego što se uključenje u ispitivanje ograničilo na bolesnike s mCRC s „divljim tipom“ eksona 2 KRAS-a.
English: In time related endpoints no trends indicating clinical benefit could be shown for patients who received cetuximab in combination with the XELOX regimen.
Croatian: Kod ishoda povezanih s vremenom nisu se mogli pokazati trendovi koji bi upućivali na kliničku korist za bolesnike koji su primili cetuksimab u kombinaciji sa XELOX protokolom.
English: The risk for anaphylactic reactions is much increased in patients with a history of allergy to red meat or tick bites or positive results of tests for IgE antibodies against cetuximab (α-1-3-galactose).
Croatian: Rizik od pojave anafilaktičkih reakcija jako je povećan u bolesnika s poznatom alergijom na crveno meso ili ugrize krpelja ili pozitivnim rezultatima testova na IgE protutijela protiv cetuksimaba (α-1-3-galaktoze).
English: Skin lesions induced by cetuximab may predispose patients to superinfections (e.g. with S. aureus), which may lead to subsequent complications, e.g. cellulitis, erysipelas, or, potentially with fatal outcome, staphylococcal scalded skin syndrome, necrotising fasciitis or sepsis.
Croatian: Lezije kože uzrokovane cetuksimabom mogu povećati sklonost bolesnika prema superinfekcijama (npr. sa S. aureus), što može dovesti do posljedičnih komplikacija, npr. celulitisa, erizipela, ili, potencijalno s fatalnim ishodom, stafilokoknog sindroma opečene kože, nekrotizirajućeg fasciitisa ili sepse.
English: The European Medicines Agency has waived the obligation to submit the results of studies with cetuximab in all subsets of the paediatric population in the indications adenocarcinoma of the colon and rectum and oropharyngeal, laryngeal or nasal epithelial carcinoma (excluding nasopharyngeal carcinoma or lymphoepithelioma, see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka cetuksimaba u svim podskupinama pedijatrijske populacije u indikacijama adenokarcinom kolona i rektuma te orofarinksa, grkljana ili karcinoma epitela nosa (isključujući nazofaringealni karcinom ili limfoepiteliom, vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: • metastatic cancer of the large intestine.
Croatian: • metastatskog karcinoma debelog crijeva.
English: • with polypropylene (PP) syringes for syringe pump.
Croatian: • polipropilenskim (PP) štrcaljkama za injekcijsku pumpu.
English: In combination with capecitabine and oxaliplatin (XELOX) the frequency of severe diarrhoea may be increased.
Croatian: U kombinaciji s kapecitabinom i oksaliplatinom (XELOX) može se povećati učestalost teškog proljeva.
English: Intravenous infusions of cetuximab exhibited dose-dependent pharmacokinetics at weekly doses ranging from 5 to 500 mg/m body surface area.
Croatian: Intravenska infuzija cetuksimaba pokazala je farmakokinetiku ovisnu o dozi u tjednim dozama u rasponu od 5 do 500 mg/m2 tjelesne površine tijela.
English: The combination of Erbitux with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant RAS metastatic colorectal cancer (mCRC) or for whom RAS mCRC status is unknown (see also section 4.4).
Croatian: Kombinacija Erbituxa s kemoterapijom koja sadrži oksaliplatin kontraindicirana je kod bolesnika s RAS mutiranim metastatskim kolorektalnim karcinomom (mCRC) ili kod bolesnika s mCRC za koje nije poznat RAS status (vidjeti također dio 4.4).
English: Erbitux 5 mg/mL solution for infusion is supplied in vials containing 20 mL or 100 mL.
Croatian: Erbitux 5 mg/ml otopina za infuziju isporučuje se u bočicama koje sadrže 20 ml ili 100 ml.
English: Medium to high-potency topical corticosteroids or oral tetracyclines have been used for the treatment of skin reactions.
Croatian: Topikalni kortikosteroidi umjerene do velike jakosti ili oralni tetraciklini korišteni su za liječenje kožnih reakcija.
English: Some of these reactions may be anaphylactic or anaphylactoid in nature or represent a cytokine release syndrome (CRS).
Croatian: Neke od ovih reakcija mogu biti anafilaktičke ili anafilaktoidne prirode ili predstavljati sindrom oslobađanja citokina.
English: In a study of cetuximab administered in combination with irinotecan, the mean cetuximab trough levels were 50.0 microgram per mL in week 12 and 49.4 microgram per mL in week 36.
Croatian: U ispitivanju cetuksimaba primijenjenog u kombinaciji s irinotekanom srednje najniže razine cetuksimaba iznosile su 50,0 mikrograma po ml u tjednu 12 i 49,4 mikrograma po ml u tjednu 36.
English: Main side effects concerning the skin include:
Croatian: Glavne nuspojave povezane s kožom uključuju:
English: The initial dose is 400 mg cetuximab per m body surface area.
Croatian: Početna doza je 400 mg cetuksimaba po m tjelesne površine.
English: Cetuximab blocks binding of endogenous EGFR ligands resulting in inhibition of the function of the receptor.
Croatian: Cetuksimab blokira vezanje endogenih EGFR liganda što dovodi do inhibicije receptorske funkcije.
English: This may lead to infectious complications including life-threatening conditions, especially if you experience skin reactions, inflammation of the lining of the intestine and mouth or diarrhoea.
Croatian: To može voditi do infekcijskih komplikacija koja uključuju stanja opasna po život, naročito ako je kod Vas došlo do reakcija kože, upale sluznice crijeva i usta ili proljeva.
English: However, in preclinical wound healing models EGFR selective tyrosine kinase inhibitors were shown to retard wound healing.
Croatian: Međutim, u pretkliničkim modelima zacjeljivanja pokazano je da EGFR selektivni inhibitori tirozin kinaze usporavaju zacjeljivanje rana.
English: The 5 randomised studies investigated a total of 3734 patients with metastatic colorectal cancer, in whom EGFR expression was detectable and who had an ECOG performance status of ≤ 2.
Croatian: Pet randomiziranih ispitivanja obuhvaćala su ukupno 3734 bolesnika s metastatskim kolorektalnim karcinomom, kod kojih se mogla detektirati ekspresija EGFR-a i kod kojih je indeks općeg statusa po ECOG skali bio ≤
English: Skin reactions may develop in more than 80% of patients and mainly present as acne-like rash and/or, less frequently, as pruritus, dry skin, desquamation, hypertrichosis, or nail disorders (e.g. paronychia).
Croatian: Kožne se reakcije mogu razviti kod više od 80% bolesnika i najčešće se javljaju u vidu osipa koji nalikuje na akne i/ili manje učestalo, kao svrbež, suha koža, deskvamacija, hipertrihoza ili promjene noktiju (npr. paronihija).
English: Only patients with adequate renal and hepatic function have been investigated to date (serum creatinine  1.5fold, transaminases  5fold and bilirubin  1.5fold the upper limit of normal).
Croatian: Do danas su ispitani samo bolesnici s odgovarajućom bubrežnom i jetrenom funkcijom (serumski kreatinin ≤ 1,5 puta, transaminaze ≤ 5 puta i bilirubin ≤ 1,5 puta od gornje granice normale).
English: Your doctor will therefore monitor your blood and general condition for signs of infection (see also 'Side effects in combination with other anticancer treatments' in section 4).
Croatian: Liječnik će nadzirati Vašu krvnu sliku i opći zdravstveni status tražeći znakove pojave infekcije (pogledajte također „Nuspojave u kombinaciji s drugim lijekovima protiv karcinoma“ u dijelu 4).
English: From the KRAS evaluated population 64% of the patients (192) had KRAS wildtype tumours and 108 patients KRAS mutations.
Croatian: U ispitivanoj populaciji KRAS-a 64% bolesnika (192) imalo je tumore s „divljim tipom“ KRAS-a, a 108 mutacije KRAS-a.
English: Combination treatment
Croatian: Kombinirano liječenje
English: Erbitux 5 mg/mL is compatible
Croatian: Erbitux 5 mg/ml je kompatibilan s
English: No studies on the effects on the ability to drive and use machines have been performed.
Croatian: Studije o utjecaju na sposobnost upravljanja vozilima i rada sa strojevima nisu provedene.
English: Transfer the Erbitux into a sterile evacuated container or bag.
Croatian: Prenesite Erbitux u sterilni prazni spremnik ili vrećicu.
English: In combination with local radiation therapy of the head and neck area, additional undesirable effects were those typical of radiation therapy (such as mucositis, radiation dermatitis, dysphagia or leukopenia, mainly presenting as lymphocytopenia).
Croatian: U kombinaciji s lokalnim zračenjem u području glave i vrata, dodatne nuspojave bile su one koje su tipične za zračenje (kao što su mukozitis, radijacijski dermatitis, disfagija ili leukopenija, većinom kao limfocitopenija).
English: • redness and swelling of the palms of the hands or the soles of the feet which may cause the skin to peel (hand-foot syndrome)
Croatian: • crvenjenje i oticanje dlanova ili tabana što može izazvati ljuštenje kože (sindrom šake i stopala)
English: Erbitux is usually infused into a vein (given as a drip) once a week.
Croatian: Erbitux se obično daje infuzijom u venu (kao drip) jednom tjedno.
English: Careful monitoring is recommended in such patients, in particular in those who experience skin lesions, mucositis or diarrhoea that may facilitate the occurrence of infections (see section 4.8).
Croatian: Preporučuje se pomno praćenje ovih bolesnika, naročito onih koji imaju lezije kože, mukozitis ili proljev koji mogu pogodovati pojavi infekcija (vidjeti dio 4.8.).
English: If you receive Erbitux in combination with other anticancer medicines, these medicines must be administered at least 1 hour after the end of the Erbitux infusion.
Croatian: Ako Erbitux primate u kombinaciji s drugim lijekovima za liječenje karcinoma, ti se lijekovi moraju dati najmanje 1 sat nakon isteka infuzije Erbituxa.
English: Severe infusion-related reactions, including anaphylactic reactions, may commonly occur, in some cases with fatal outcome.
Croatian: Često se mogu javiti teške reakcije povezane s infuzijom uključujući anafilaktičke reakcije, u nekim slučajevima s fatalnim ishodom.
English: Cetuximab should be used with caution in patients with a history of keratitis, ulcerative keratitis or severe dry eye.
Croatian: Cetuksimab treba koristiti oprezno u bolesnika s anamnezom keratitisa, ulceroznog keratitisa ili jako suhim okom.
English: Mild or moderate infusion-related reactions are very common comprising symptoms such as fever, chills, dizziness, or dyspnoea that occur in a close temporal relationship mainly to the first cetuximab infusion.
Croatian: Vrlo su česte blage do umjerene reakcije povezane s infuzijom a uključuju simptome poput vrućice, zimice, omaglice ili dispneje koji se pojavljuju u bliskom vremenskom odnosu, poglavito s prvom infuzijom cetuksimaba.
English: In addition, cetuximab was investigated in combination with chemotherapy in an investigator-initiated randomised controlled phase-III study (COIN, COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy).
Croatian: Pored toga, cetuksimab je ispitan u kombinaciji s kemoterapijom u randomiziranom kontroliranom ispitivanju faze III iniciranom od samog ispitivača (COIN, kontinuirana kemoterapija i cetuksimab ili intermitentna kemoterapija).
English: They normally occur during the infusion, within 1 hour afterwards, or sometimes also after this period.
Croatian: U pravilu se pojavljuju tijekom infuzije, unutar 1 sata nakon infuzije ili ponekad također i nakon tog razdoblja.
English: Following disease progression, treatment with EGFR-targeting agents was initiated in 50% of patients in the irinotecan-alone arm.
Croatian: Po napredovanju bolesti, liječenje lijekovima koji ciljaju EGFR započeto je kod 50% bolesnika u skupini koja je primala samo irinotekan.
English: Severe infusion-related reactions, in some cases with fatal outcome (see section 4.4); fatigue.
Croatian: Teške reakcije povezane s infuzijom, u nekim slučajevima sa smrtnim ishodom (vidjeti dio 4.4); umor.
English: • irritation and redness of the eye
Croatian: • iritacija i crvenilo oka
English: Erbitux is contraindicated in patients with known severe (grade 3 or 4) hypersensitivity reactions to cetuximab.
Croatian: Erbitux je kontraindiciran kod bolesnika s poznatom teškom (3. i 4. stupanj) reakcijom preosjetljivosti na cetuksimab.
English: The majority of patients included had an ECOG performance status of ≤ 1.
Croatian: 2. Kod većine uključenih bolesnika ECOG indeks bio je ≤ 1.
English: 20 mL or 100 mL of solution in a vial (Type I glass) with a stopper (halobutyl rubber) and a seal (aluminium/polypropylen).
Croatian: 20 ml ili 100 ml otopine u bočici (staklo tipa I) s čepom (halobutilna guma) i zaštitnim zatvaračem (aluminij/polipropilen).
English: RAS status was evaluable in tumour samples of 407 KRAS exon 2 wild-type patients reflecting 69% of the overall KRAS exon 2 wild-type patient population (592 patients).
Croatian: RAS-status mogao se procijeniti na uzorcima tumora 407 bolesnika s „divljim tipom“ eksona 2 KRAS-a koji su činili 69% ukupne populacije bolesnika s „divljim tipom“ eksona 2 KRAS-a (592 bolesnika).
English: The use of cetuximab in combination with chemo-radiotherapy has so far not been adequately investigated.
Croatian: Primjena cetuksimaba u kombinaciji s kemoradioterapijom dosad nije odgovarajuće ispitana.
English: More than 80 out of 100 patients are likely to experience side effects involving the skin.
Croatian: Više od 80 na 100 bolesnika bi moglo dobiti nuspojave vezane uz kožu.
English: Cetuximab is a chimeric monoclonal IgG1 antibody that is specifically directed against the epidermal growth factor receptor (EGFR).
Croatian: Cetuksimab je kimerno monoklonsko IgG1 protutijelo koje je specifično usmjereno prema receptoru za epidermalni čimbenik rasta (EGFR).
English: Cetuximab binds to the epidermal growth factor receptor (EGFR), an antigen on the surface of certain cancer cells.
Croatian: Cetuksimab se veže na receptor epidermalnog čimbenika rasta (EGFR), antigen koji se nalazi na površini određenih stanica karcinoma.
English: Analyses on the RAS wild-type population are required to appropriately evaluate these data
Croatian: Za odgovarajuću procjenu ovih podataka potrebna je analiza populacije s „divljim tipom“
English: Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck
Croatian: Erbitux je indiciran za liječenje bolesnika s karcinomom pločastih stanica glave i vrata
English: Cetuximab as a single agent or in combination with chemotherapy was investigated in 5 randomised controlled clinical studies and several supportive studies.
Croatian: Cetuksimab je kao samostalan lijek ili u kombinaciji s kemoterapijom ispitivan u 5 randomiziranih kontroliranih kliničkih ispitivanja i nekoliko suportivnih ispitivanja.
English: Combination with other anticancer treatments
Croatian: Kombinacija s drugim lijekovima za liječenje karcinoma
English: • acne-like skin alterations
Croatian: • promjene na koži nalik aknama
English: In a randomised controlled clinical study with 424 patients, reporting rates of severe acute radiation dermatitis and mucositis as well as of late radiation-therapy-related events were slightly higher in patients receiving radiation therapy in combination with cetuximab than in those receiving radiation therapy alone.
Croatian: U randomiziranom kontroliranom kliničkom ispitivanju s 424 bolesnika opisani stupnjevi teških akutnih radijacijskih dermatitisa i mukozitisa te kasnijih pojava povezanih sa zračenjem bili su nešto viši kod bolesnika liječenih kombinacijom zračenja i cetuksimaba, nego kod onih koji su samo zračeni.
English: Cetuximab was started one week before radiation therapy and administered at the doses described in section 4.2 until the end of the radiation therapy period.
Croatian: Liječenje cetuksimabom započelo je jedan tjedan prije zračenja u dozama opisanim u poglavlju 4.2 i trajalo je do kraja razdoblja zračenja.
English: Cetuximab plus FOLFOX4
Croatian: Cetuksimab i FOLFOX4
English: Side effects concerning the lungs
Croatian: Nuspojave povezane s plućima
English: Cetuximab pharmacokinetics were studied when cetuximab was administered as monotherapy or in combination with concomitant chemotherapy or radiation therapy in clinical studies.
Croatian: Farmakokinetika cetuksimaba proučavana je kad se cetuksimab primjenjivao kao monoterapija ili u kombinaciji s istodobno primijenjenom kemoterapijom ili zračenjem u kliničkim ispitivanjima.
English: Cetuximab in combination with radiation therapy for locally advanced disease
Croatian: Cetuksimab u kombinaciji sa zračenjem za lokalno uznapredovalu bolest
English: • For administration with infusion pump or gravity drip (undiluted): Calculate the required volume of Erbitux.
Croatian: • Primjena s infuzijskom pumpom ili običnom infuzijom (nerazrijeđen): Izračunajte potrebni volumen Erbituxa.
English: Toxicity studies with co-administration of cetuximab and chemotherapeutic agents have not been performed.
Croatian: Ispitivanja toksičnosti zajedničke primjene cetuksimaba i kemoterapeutika nisu provedena.
English: What Erbitux contains
Croatian: Što Erbitux sadrži
English: Connect the infusion line and prime it with Erbitux before starting the infusion.
Croatian: Spojite infuzijsku liniju i ispunite ju Erbituxom prije započinjanja infuzije.
English: Please read 'Infusion-related side effects' in section 4 for details, as they may have serious consequences for you, including life-threatening conditions.
Croatian: Pročitajte „Nuspojave povezane s infuzijom“ u dijelu 4 za pojedinosti jer mogu imati ozbiljne posljedice za Vas uključujući i po život opasna stanja.
English: Side effects concerning the skin
Croatian: Nuspojave povezane s kožom
English: Tumour samples from approximately 81% of patients were analysed retrospectively for KRAS expression, of which 55% were KRAS wild-type.
Croatian: Uzorci tumora od približno 81% bolesnika analizirani su retrospektivno na ekspresiju KRAS-a; 55% je bilo „divlji tip“ KRAS-a.
English: Study data demonstrate that patients with metastatic colorectal cancer and activating RAS mutations are highly unlikely to benefit from treatment with cetuximab or a combination of cetuximab and chemotherapy and as add-on to FOLFOX4 a significant negative effect on progression-free survival time (PFS) was shown.
Croatian: Podaci iz ispitivanja pokazuju da je vrlo malo vjerojatno da će bolesnici s metastatskim kolorektalnim karcinomom i aktivirajućim mutacijama RAS-a imati koristi od liječenja cetuksimabom ili kombinacijom cetuksimaba i kemoterapije, a kao dodatno liječenje protokolu FOLFOX4 cetuksimab je pokazao značajno negativan učinak na vrijeme preživljenja bez napredovanja bolesti (PFS).
English: Severe infusion-related side effects include:
Croatian: Teške nuspojave povezane s infuzijom uključuju:
English: There are no data on the effect of cetuximab on human fertility.
Croatian: Nema podataka o učinku cetuksimaba na plodnost u ljudi.
English: Similarly, the pharmacokinetics of irinotecan were unchanged when cetuximab was co-administered.
Croatian: Slično tome, farmakokinetika irinotekana je bila nepromijenjena nakon istodobne primjene cetuksimaba.
English: Very common side effects (may affect more than 1 in 10 people)
Croatian: Vrlo česte nuspojave (mogu se pojaviti kod više od 1 na 10 osoba)
English: Cetuximab is a chimeric monoclonal IgG1 antibody produced in a mammalian cell line (Sp2/0) by recombinant DNA technology.
Croatian: Cetuksimab je kimerno monoklonsko IgG1 protutijelo proizvedeno u staničnoj liniji sisavaca (Sp2/0) tehnologijom rekombinantne DNK.
English: Tumour samples from approximately 81% of patients were analysed retrospectively for KRAS expression.
Croatian: Uzorci tumora od približno 81% bolesnika analizirani su retrospektivno na ekspresiju gena KRAS.
English: EGFR activates proteins called RAS. RAS proteins play an important role in the EGFR pathway -a complex signalling cascade which is involved in the development and progression of cancer.
Croatian: RAS bjelančevine imaju važnu ulogu u EGFR putu - kompleksnoj signalnoj kaskadi koja je uključena u razvoj i napredovanje karcinoma.
English: In tumours, activation of RAS by EGFR contributes to EGFR-mediated increased proliferation, survival and the production of pro-angiogenic factors.
Croatian: Kod tumora, aktiviranje gena RAS putem EGFR-a pridonosi povećanoj proliferaciji posredovanoj EGFR-om te preživljenju i tvorbi proangiogenih faktora.
English: Erbitux may cause side effects concerning the eyes.
Croatian: Erbitux može uzrokovati nuspojave na očima.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for infusion contains 5 mg cetuximab.
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml otopine za infuziju sadrži 5 mg cetuksimaba.